by | Jun 27, 2024 | Publications
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):952-956. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.046. ABSTRACT Multiple myeloma (MM) is an incurable malignant plasma cell diseases, the incidence of which is increasing year by year. The application of...
by | Jun 27, 2024 | Publications
Biomolecules. 2024 Jun 19;14(6):725. doi: 10.3390/biom14060725. ABSTRACT Immunomodulatory imide drugs (IMiDs) play a crucial role in the treatment landscape across various stages of multiple myeloma. Despite their evident efficacy, some patients may exhibit primary...
by | Jun 27, 2024 | Publications
Biomedicines. 2024 May 23;12(6):1153. doi: 10.3390/biomedicines12061153. ABSTRACT INTRODUCTION: After receiving different lines of treatment, multiple myeloma patients tend to present with less secretory and more frequent extramedullary disease. These features make...
by | Jun 27, 2024 | Publications
Cancers (Basel). 2024 Jun 19;16(12):2263. doi: 10.3390/cancers16122263. ABSTRACT The outcome of multiple myeloma (MM) has significantly improved in the last few decades due to several factors such as new biological discoveries allowing to better stratify disease risk,...
by | Jun 27, 2024 | Publications
Int J Mol Sci. 2024 Jun 11;25(12):6431. doi: 10.3390/ijms25126431. ABSTRACT Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; n = 395) randomizing VAD induction...
by | Jun 27, 2024 | Publications
Front Oncol. 2024 Jun 11;14:1404744. doi: 10.3389/fonc.2024.1404744. eCollection 2024. ABSTRACT BACKGROUND: Multiple myeloma (MM), a malignant disease of plasma cells originating in the bone marrow, is influenced significantly by genetic factors. Although plasma...
